Elizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, Ann Hanna, Brandie C Taylor, Violeta Sanchez, Juliana Bronzini, Susan R Opalenik, Melinda E Sanders, Julia Wulfkuhle, Rosa I Gallagher, Henry Gomez, Claudine Isaacs, Vijaya Bharti, John T Wilson, Tarah J Ballinger, Cesar A Santa-Maria, Payal D Shah, Elizabeth C Dees, Brian D Lehmann, Vandana G Abramson, Gillian L Hirst, Lamorna Brown Swigart, Laura J van ˈt Veer, Laura J Esserman, Emanuel F Petricoin, Jennifer A Pietenpol, Justin M Balko
UNLABELLED: Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers...
April 24, 2024: Cancer Res Commun